| Harnessing the E3 ligase KEAP1 for targeted protein degradation J Wei, F Meng, KS Park, H Yim, J Velez, P Kumar, L Wang, L Xie, H Chen, ... Journal of the American Chemical Society 143 (37), 15073-15083, 2021 | 97 | 2021 |
| Discovery of the first-in-class G9a/GLP covalent inhibitors KS Park, Y Xiong, H Yim, J Velez, N Babault, P Kumar, J Liu, J Jin Journal of medicinal chemistry 65 (15), 10506-10522, 2022 | 29 | 2022 |
| Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2 J Velez, B Dale, KS Park, HÜ Kaniskan, X Yu, J Jin European Journal of Medicinal Chemistry 267, 116154, 2024 | 10 | 2024 |
| Discovery of the first lactate dehydrogenase proteolysis targeting chimera degrader for the treatment of pancreatic cancer N Sun, M Kabir, Y Lee, L Xie, X Hu, J Velez, X Chen, HU Kaniskan, J Jin Journal of medicinal chemistry 66 (1), 596-610, 2022 | 8 | 2022 |
| Recent advances in developing degraders & inhibitors of lysine methyltransferases J Velez, HÜ Kaniskan, J Jin Current Opinion in Chemical Biology 76, 102356, 2023 | 6 | 2023 |
| Discovery of the First-in-class G9a/GLP PROTAC Degrader J Velez, Y Han, H Yim, P Yang, Z Deng, K Park, M Kabir, HU Kaniskan, ... Journal of Medicinal Chemistry 67 (8), 6397-6409, 2024 | 5 | 2024 |
| Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome SE Wang, Y Xiong, MA Jang, KS Park, M Donahue, J Velez, J Jin, Y Jiang Molecular Therapy, 2024 | 3 | 2024 |
| Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer’s disease proteopathology for precision medication X Chen, L Xie, R Sheehy, Y Xiong, A Muneer, J Wrobel, KS Park, J Liu, ... Research Square, 2023 | 3 | 2023 |
| Discovery and Characterization of Novel Lysine Methyltransferase-Targeting PROTAC Degraders J Velez Icahn School of Medicine at Mount Sinai, 2024 | | 2024 |
| Abstract A055: Discovery of a novel, highly potent VHL-recruiting EZH2 PROTAC degrader targeting MLL-r AML J Velez, X Yu, B Dale, KS Park, H Ümit Kaniskan, J Jin Molecular Cancer Therapeutics 22 (12_Supplement), A055-A055, 2023 | | 2023 |
